Open AccessEvaluating the Cost-Effectiveness of Celecoxib versus Ibuprofen and Naproxen in Patients with Osteoarthritis in United Arab Emirates Based on the PRECISION Trial
Author(s) -
Viktor Chirikov,
Chris Walker,
Jennifer Stephens,
Patricia Schepman,
Richard Chambers,
Mahmoud Bakir,
Gregory W. Poorman,
Seema Haider,
Mohammed Farghaly
Publication year - 2021
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s280556
Subject(s) - celecoxib , naproxen , medicine , ibuprofen , osteoarthritis , adverse effect , diclofenac , pharmacology , alternative medicine , pathology
Data on osteoarthritis patients from the PRECISION trial were used to evaluate the cost-effectiveness of celecoxib (100 mg twice daily) versus ibuprofen (600-800 mg three times daily) and naproxen (375-500 mg twice daily). The perspective was that of the United Arab Emirates (UAE) healthcare system.